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Abstract
Background: Early metastasis and infiltration are survival limiting characteristics of pancreatic ductal
adenocarcinoma (PDAC). Thus, PDAC is likely to harbor alterations in metastasis suppressor genes that may provide
novel diagnostic and therapeutic opportunities. This study investigates a panel of metastasis suppressor genes in
correlation to PDAC phenotype and examines promoter methylation for regulatory influence on metastasis
suppressor gene expression and for its potential as a diagnostic tool.
Methods: Metastatic and invasive potential of 16 PDAC cell lines were quantified in an orthotopic mouse model
and mRNA expression of 11 metastasis suppressor genes determined by quantitative RT-PCR. Analysis for promoter
methylation was performed using methylation specific PCR and bisulfite sequencing PCR. Protein expression was
determined by Western blot.
Results: In general, higher metastasis suppressor gene mRNA expression was not consistent with less aggressive
phenotypes of PDAC. Instead, mRNA overexpression of several metastasis suppressor genes was found in PDAC cell
lines vs. normal pancreatic RNA. Of the investigated metastasis suppressor genes, only higher AKAP12 mRNA
expression was correlated with decreased metastasis (P < 0.05) and invasion scores (P < 0.01) while higher
SERPINB5 mRNA expression was correlated with increased metastasis scores (P < 0.05). Both genes’ promoters
showed methylation, but only increased SERPINB5 methylation was associated with loss of mRNA and protein
expression (P < 0.05). SERPINB5 methylation was also directly correlated to decreased metastasis scores (P < 0.05).
Conclusions: AKAP12 mRNA expression was correlated to attenuated invasive and metastatic potential and may be
associated with less aggressive phenotypes of PDAC while no such evidence was obtained for the remaining
metastasis suppressor genes. Increased SERPINB5 mRNA expression was correlated to increased metastasis and
mRNA expression was regulated by methylation. Thus, SERPINB5 methylation was directly correlated to metastasis
scores and may provide a diagnostic tool for PDAC.
Background
Pancreatic ductal adenocarcinoma (PDAC) represents
~95% of all pancreatic malignancies and has the poorest
survival rate for any solid cancer with 5-year survival
rates below 5% and a median survival of 6 months [1].
Complete surgical resection is the only curative treat-
ment option but patients are often diagnosed at late
stages when surrounding tissue has already been infil-
trated and metastasis has occurred. Lack of typical
clinical symptoms, unavailability of methods for early
detection and resistance to chemotherapy additionally
contribute to the high mortality rates. Tumor biology,
clinical characteristics and therapeutic response rates
suggest specific alterations in PDAC that set it apart
from other types of cancer [2], emphasizing the need for
specific diagnostic and therapeutic targets in this tumor
entity.
Genes that can inhibit metastasis and invasion are
likely to be deregulated in PDAC and could be candi-
dates for novel therapeutic and diagnostic strategies.
Metastasis suppressor genes are defined as inhibitors of
metastasis at any step of the metastatic cascade that do
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discovery of these endogenous molecules that can exclu-
sively inhibit metastasis, and the understanding of their
actions, suggest that metastasis is an amenable thera-
peutic target. However, only few of the currently known
metastasis suppressor genes have been examined in pan-
creatic cancer so far, their expression and also their
means of regulation in this tumor entity remain largely
uninvestigated.
DNA methylation is a well known mechanism for loss
of expression in a variety of tumors, including PDAC.
Aberrant methylation appears to be a frequent epige-
netic event for a number of genes in pancreatic cancer
that may play a role in its tumorigenesis, local progres-
sion and metastasis [4,5]. Hypermethylation has addi-
tionally been shown to coincide with tumor
dedifferentiation [6,7]. At the same time, hypomethyla-
tion resulting in overexpression of affected genes has
also been reported in clinical PDAC samples and -cell
lines [8].
These findings could be exploited in diagnostic
strategies based upon the detection of methylation in
body fluids such as serum, urine, pancreatic juice or
sputum [9].
In this study, a panel of genes, representing the known
metastasis suppressor genes at the time of conception of
the study [10], was investigated in order to determine
potential candidate genes for PDAC therapy and -detec-
tion. By searching for metastasis suppressor gene
expression patterns in correlation to PDAC phenotype,
relevant gene candidates were identified for further
research. These candidates were subsequently investi-
gated for promoter methylation as a regulatory element
that may also serve as an instrument of PDAC
detection.
Methods
Analyses were carried out for 11 metastasis suppressor
g e n e sa sr e v i e w e db yS h e v d ee ta l .[ 1 0 ] :AKAP12,
BRMS1, CD82, CDH1, KiSS-1, MAP2K4, MED23,
NDRG1, SERPINB5, TIMP3 and TXNIP.A l t e r n a t i v e
names and accession numbers are provided in Addi-
tional file 1.
A total of 18 human PDAC cell lines were analyzed
(Table 1). Cells were maintained in recommended
growth media, and all media were supplemented with
10% heat inactivated fetal bovine serum (Gibco/Invitro-
gen, Karlsruhe, Germany) and were mycoplasma nega-
tive. For culturing, they were incubated at 37°C in
humidified air with 5% or 10% CO2. The medium was
replaced twice a week, and cells were maintained by
serial passaging after trypsinization with 0.1% trypsin.
An orthotopic implantation tumor model using four-
week-old male nude mice (Crl:NU/NU-nuBR) was
previously performed, including calculation of metastasis
and invasion scores [11]. All experiments were con-
ducted in accordance with the national guidelines for
t h ec a r ea n du s eo fl a b o r a t o r ya n i m a l s ,a n dt h ee x p e r i -
mental protocol was approved by the state agency for
animal welfare of North Rhine-Westphalia
(9.93.2.10.36.07.257, LANUV, NRW, Germany). In brief,
Four-week-old male nude mice (Crl:NU/NU-nuBR)
were used as tumor donors and received a subcutaneous
injection of each human PDAC cell line. The mice were
euthanized after 3 to 4 weeks and the donor tumors
were collected. Donor tumor fragments were inserted
orthotopically into the recipient mouse’s pancreatic par-
enchyma. After 12 weeks of tumor growth clinical signs
of tumor burden, primary tumor volume, local infiltra-
tion, and patterns of local and systemic metastases were
assessed with a standardized dissemination score. Local
infiltration was determined at the abdominal organs, the
retroperitoneum and the abdominal wall. Metastasis was
determined at liver, lymph nodes in the upper abdomen,
diaphragm, mesentery and retroperitoneum; isolated
tumor nodules with no anatomic connection to the pri-
mary tumor were also defined as metastases. Score
values represent mean sums of the obtained credit
Table 1 Tumor biology of PDAC cell lines
Metastasis
Score
Cell Line Origin Invasion
Score
Cell Line Origin





PT 0.56 Capan2 PT
0.75 PaTu
8988T
LM 0.94 Panc1 PT
0.90 Panc1 PT 0.98 A818 AS
0.92 BxPC3 PT 1.50 BxPC3 PT
1.24 A818 AS 2.08 PaTu
8988T
LM
1.44 PT45 PT 2.49 PT45 PT
2.16 Capan1 PT 3.27 Capan1 PT
2.58 MiaPaCa2 PT 3.04 HPAF2 AS
3.54 SU 86.86 LM 3.43 SU 86.86 LM
3.55 Suit 0028 LM 3.53 MPanc 96 PT
4.29 HPAF2 AS 3.99 PaTu
8988S
LM
4.29 MPanc 96 PT 5.60 MiaPaCa2 PT
4.38 AsPc1 AS 6.25 Suit 007 LM
4.90 PaTu
8988S
LM 6.44 AsPc1 AS
5.49 Suit 007 LM 8.82 Suit 0028 LM
N/A HS766T NM N/A HS766T NM
N/A PL45 PT N/A PL45 PT
Score-based assessment of metastatic and invasive potential. Cell line origins:
PT = primary tumor, AS = ascites, LM = liver metastasis, NM = Lymph node
metastasis. Cell lines PL45 and HS766T did not grow tumors in the mouse
model but were included in methylation assays.
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(n = 10). The results were compiled into a score each
for metastasis and invasion.
DNA extraction from cultured cell lines was
performed with DNeasy Blood & Tissue kits (Qiagen,
Hildesheim, Germany) according to the manufacturer’s
specifications. DNA samples were stored at -20°C. RNA
extraction was performed from cultured cell lines using
RNeasy Mini kits (Qiagen) according to the manufac-
turer’s specifications. A total RNA preparation from
normal human pancreas was acquired from Applied Bio-
systems/Applera (Darmstadt, Germany). RNA samples
were stored at -80°C. CDNA was generated with High
Capacity cDNA Reverse Transcription kits (Applied Bio-
systems) according to the manufacturer’s specifications.
CDNA was stored at -20°C. Purity and concentration of
nucleic acids were measured in a biophotometer
(Eppendorf; Hamburg, Germany). Bisulfite modification
of DNA was performed with EpiTect Bisulfite kits (Qia-
gen) according to the manufacturer’s specifications.
Obtained products were stored at -20°C.
MSP Primers were designed to be located in CpG-
islands within the promoter region of each gene. Primer
sequences, annealing temperatures and product sizes are
provided in Additional file 2. All primers were obtained
from Operon (Hildesheim, Germany) and used at final
concentrations of 2 μM. Methylation specific PCR
(MSP) was performed as a hot-start PCR in a mastercy-
cler gradient (Eppendorf) under the following conditions
in a total reaction volume of 25 μl. The reaction was
hot-started using 1 U of GoTaq (Promega, Mannheim,
Germany) after 5 min at 95°C. 35 cycles were run using
the following parameters: 0:30 min at Ta, 1 min at 72°C.
Final extension was allowed for 10 min at 72°C. Pro-
ducts were kept at 4°C until further use (maximum of
24 h). Unmethylated EpiTect Control DNA (Qiagen)
served as a negative methylation control. DNA isolated
from peripheral blood from healthy individuals was arti-
ficially methylated using the SSSI Methylation Kit (NEB,
Ipswich, MA, USA) according to the manufacturer’s
specifications and used as a positive control for the
methylation-specific primers after bisulfite modification.
No-template controls were conducted in parallel.
BSP-Primers were designed to amplify a region con-
taining ~20-40 CpG-dinucleotides within the CpG-
islands in the promoter region of each gene. Primer
sequences, annealing temperatures, number of CpGs
sequenced and product sizes are provided in Additional
file 3. Each primer included an additional M13 sequence
which was used in the following sequencing reaction.
Primers were obtained from Operon and used at final
concentrations of 1.4 μM. Bisulfite sequencing PCR
(BSP) was performed using 0.7 U of HotStarTaq Plus
(Qiagen) per reaction. After 5 min of denaturation at
95°C, an initial 5 cycles were run with 0:30 min at Ta1,
1 min at 72°C followed by 35 cycles with 0:30 min at
Ta2, 1 min at 72°C. Final extension was allowed for 10
min at 72°C. Products were kept at 4°C until further use
for a maximum of 24 h. No-template controls were per-
formed in parallel. PCR products were run on an agar-
ose gel stained with ethidium bromide and the bands
were excised with clean scalpels. Agarose and contami-
nants were removed using QiaQuick Gel Extraction kits
(Qiagen) according to the manufacturer’s specifications.
Dye terminator sequencing reactions of the cleaned PCR
products were performed with Quickstart reaction kits
(Beckman Coulter; Krefeld, Germany) and M13 sequen-
cing primers according to the manufacturer’s specifica-
tions. Analysis of the sequencing reactions was
performed on a Beckman Coulter 8800 Sequencer. The
results from direct sequencing were analyzed with the
Beckman Coulter CEQ 8800 Genetic Analysis System
s o f t w a r ev 9 . 0u s i n gC -t oT - p e a kr a t i o st od e f i n ea
CpG-dinucleotide as methylated, unmethylated or het-
erogeneously methylated. Point values were assigned to
each CpG-dinucleotide according to its methylation sta-
tus as follows: unmethylated: 0; heterogeneously methy-
lated: 1; methylated: 2. A methylation-score was
calculated for each gene in each cell line by using the
average point value of all investigated CpG-dinucleotides
for that gene.
Western Blots were performed as previously described
[11]. The following adaptations were made: 15 μg( SER-
PINB5)o r1 0μg( AKAP12)o fp r o t e i nw e r eu s e dp e r
cell line and lysates were loaded on 10% (SERPINB5)o r
4% (AKAP12) polyacrylamid gels. AKAP12 was detected
with 0.02 μg/ml rabbit anti-AKAP12 antibody (Novus
Biologicals, Littleton, CO, USA) and SERPINB5 was
detected with 0.67 μg/ml rabbit anti-SERPINB5 antibody
(Aviva Systems Biology, San Diego, CA, USA). Investi-
gated cell lines were selected to represent methylated
and unmethylated factions.
Quantitative reverse transcriptase-PCR (qRT-PCR) was
performed using TaqMan assays (Applied Biosystems) in
accordance with the manufacturer’s instructions. A nor-
mal human pancreatic RNA sample was acquired from
Ambion/Applied Biosystems (Darmstadt, Germany). The
assays used 50 ng of cDNA template per sample and
PPIB and HPRT1 were used as housekeeping genes. All
reverse transcriptase reactions included no-template
controls and real-time minus controls. RNA expression
levels were quantified using the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems). QRT-
PCR was performed in triplicate, including no-template
controls. Relative expression was calculated using the
2
-ΔΔCT Method and data was analyzed with Real-Time
StatMiner (Integromics; Madrid, Spain) and QBase
v1.3.5 [12].
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ated using 2-tailed Pearson’s correlation while correla-
tions between metastatic/invasive potential, metastasis
suppressor gene mRNA expression and promoter
methylation were investigated using 2-tailed Spearman’s
correlation and analysis of variance (ANOVA) was con-
ducted using the Kruskal-Wallis test. 95% confidence
intervals were calculated and P < 0.05 was considered
significant. SPSS 16.0 (SPSS Inc., Chicago, IL, USA) was
used for these calculations.
Results
Animal model: Tumor biology of the PDAC cell lines
Metastasis- and invasion-scores were determined for 16
of the 18 PDAC cell lines (Table 1). Two of the 18
investigated cell lines (PL45 and HS766T) did not grow
subcutaneous tumors, but mRNA expression and
methylation status analyses were still carried out for
these cell lines.
Metastasis suppressor gene mRNA expression
With the exception of MAP2K4 and TXNIP,t h em a j o r -
ity of the metastasis suppressor genes showed overex-
pression in the PDAC cell lines vs. the normal
pancreatic RNA (Figure 1; all expression data are pro-
vided in Additional file 4).
The mRNA expression of two gene-pairs was highly
positively correlated: CD82/AKAP12 (P < 0.005) and
KiSS-1/MED23 (P < 0.001). The link between KiSS-1
and MED23 (CRSP3, DRIP130) has been described pre-
viously: MED23 is a cofactor required for expression of
KiSS-1 [13]. A literature search failed to reveal a link
between CD82 and AKAP12 and to the best of our
knowledge this is the first description of their co-
expression.
Significant correlations with invasion and metastasis
scores were detected only for AKAP12 and SERPINB5
mRNA expression. Overexpression of AKAP12 was cor-
related with lower metastasis-scores (P < 0.05) and
lower invasion scores (P < 0.005). In contrast, overex-
pression of SERPINB5 correlated with increased metas-
tasis scores (P < 0.05) (Figure 2). Confirmation of these
r e s u l t sb yA N O V Aw a sp o s s i b l ef o rSERPINB5 expres-
sion vs. metastasis score (P < 0.05) and AKAP12 expres-
sion vs. infiltration score (P < 0.01).
Promoter methylation
As AKAP12 and SERPINB5 showed correlations to inva-
sion and metastasis scores, we proceeded to investigate
the genes’ promoter methylation. MSP analysis of CpG-
islands in the promoter region of the investigated genes
showed three different patterns. 1) Only the PCR with
the methylation-specific primer resulted in a band. 2)
Only the PCR with the unmethylation-specific primer
had a band. 3) Both PCRs from the same MSP showed
bands simultaneously. The results were therefore classi-
fied as methylated, unmethylated or heterogeneously
methylated (Figure 3). MSP detected methylation in 12/
18 (67%) cell lines in AKAP12 and 5/18 (28%) cell lines
in SERPINB5.
BSP produced three different signal types for the
CpG-dinucleotides within the sequenced region: 1)
Detection of a T-peak and no C-peak was classified as
an unmethylated CpG-dinucleotide. 2) Presence of a
C-peak and no T-peak was classified as a methylated
CpG-dinucleotide. 3) Superimposing C- and T-peaks
were classified as heterogeneous methylation (Figure 4a).
The signals were translated into a methylation-score
(Additional file 5). BSP showed methylation in 15/18
(83%) cell lines in AKAP12 and in 5/18 (28%) cell lines
in SERPINB5 (Figure 4b).
MSP-status was compared to BSP methylation-score and
both techniques were highly correlated across all sam-
ples (P < 0.005) showing the same results for each sam-
ple in MSP and BSP. Differing results between MSP and
BSP were however obtained for three cell lines (BxPC3,
HS766T, PL45) in AKAP12 where BSP showed methyla-
tion that was not detected by MSP.
We next investigated the influence of promoter
methylation on mRNA expression. For SERPINB5 the
methylated cell lines had the lowest mRNA expression
across all cell lines while no significant influence on
mRNA expression was detected for AKAP12 (Figure 5a).
As SERPINB5 expression was correlated both to
methylation and metastatic potential, we investigated
Figure 1 mRNA expression of metastasis suppressor genes.
Metastasis suppressor gene expression in PDAC cell lines as fold
change of expression in normal pancreatic RNA. Each dot represents
a PDAC cell line. Only MAP2K4 and TXNIP show downregulation in
PDAC cell lines while most other genes are upregulated. *not
detected in some cell lines: KiSS-1 not detected in MIAPaCa-2.
MAP2K4 not detected in A818, MPanc 96, PaTu 8902, PaTu 8988S
and PaTu 8988T. TIMP3 not detected in A818, MIAPaCa-2, PaTu 8902
and PaTu 8988T. AKAP12 and CD82 mRNA expression correlated to
one another (P < 0.005). KiSS-1 and MED23 mRNA expression
correlated to one another (P < 0.001).
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to metastatic potential. Spearman correlation revealed
that SERPINB5-methylated cell lines had significantly
lower metastasis scores than unmethylated cell lines
(P < 0.05) (Figure 5b).
Protein expression
Western Blot showed AKAP12 protein to be present in
all investigated cell lines regardless of their methylation
status and mRNA expression, making it an unlikely can-
didate for methylation based regulation. In contrast,
SERPINB5 protein was not present in methylated cell
lines which all exhibited low mRNA expression. How-
ever, SERPINB5 protein was also not detected in Suit-
007, which was not methylated for the gene and had
high SERPINB5 mRNA expression, suggesting an alter-
native mode of regulation (Figure 6). Nonetheless, our
data is in accord with reports of SERPINB5 in the litera-
ture, confirming its repression by promoter methylation
on the protein level.
Discussion
PDAC is set apart from many other tumor entities by
specific genetic alterations, a strong desmoplastic reac-
tion, early metastasis and early infiltration of neighbor-
ing organs. Its response rates to chemotherapy are
dismal and survival rates remain low despite modern
interdisciplinary approache s .I nt h i ss t u d y ,w eh a v e
investigated a panel of genes involved in key processes
of tumor dissemination in an attempt to identify pro-
mising candidates for novel therapeutic and diagnostic
strategies. Metastasis suppressor gene mRNA expression
was correlated with highly varying invasive and meta-
static phenotypes of human PDAC cell lines in an
orthotopic mouse model. Overexpression of the investi-
gated metastasis suppressors was found in most tumor
cell lines compared to normal pancreatic RNA and, in
contrast to other tumor entities, only one of the genes
in the investigated panel, AKAP12, showed a correlation
between increased mRNA expression and diminished
invasive and metastatic capabilities. AKAP12 was
Figure 2 Metastasis suppressor gene expression and tumor biology.O n l yAKAP12 and SERPINB5 mRNA expression showed correlation to
tumor phenotype. Increased AKAP12 mRNA expression was significantly correlated with reduced metastasis (P < 0.05) and invasion (P < 0.01)
while SERPINB5 expression was correlated with increased metastasis (P < 0.05).
Figure 3 Methylation specific PCR for AKAP12 and SERPINB5.
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83% (15/18) of PDAC cell lines and this overexpression
has also been reported in patient samples [14]. While
several tumor suppressor genes were overexpressed in
the PDAC cell lines vs. a control sample of normal
pancreatic RNA, it is important to note that the compo-
sition of the control sample is not ideal. Normal pan-
creas includes a variety of cell types and thus is not an
accurate control for the expression levels in normal duc-
tal cells. Microdissection of ductal pancreatic cells from
Figure 4 Bisulfite sequencing. Signals from BSP with direct sequencing. During direct sequencing cleaned up PCR products without prior
cloning were used, the sequenced signal therefore represents average methylation across the entire PCR template. A) 3 distinct signal patterns
were identified: Unmethylated cytosines with a T-signal at the CpG site, heterogeneously methylated CpGs with superimposing C- and T-signals
and methylated CpGs with a C-signal. B) BSP-analysis of promoter methylation for AKAP12 and SERPINB5. Each box represents a sequenced CpG-
dinucleotide.
Figure 5 Methylation, mRNA expression and metastasis score. A) mRNA expression was plotted against methylation-score for each cell line
to demonstrate the relevance of promoter methylation to mRNA expression. AKAP12 shows no significant correlation while SERPINB5 expression
is significantly reduced in methylated cell lines. B) Cell lines with methylated SERPINB5 promoters have significantly lower metastatic potential
(P < 0.05). MIAPaCa-2 is an outlier in the methylated group but has reduced metastatic ability compared to its strong invasive potential.
Mardin et al. BMC Cancer 2010, 10:549
http://www.biomedcentral.com/1471-2407/10/549
Page 6 of 9normal tissue could provide a more specific profile that
may better correspond to the PDAC cell lines. However,
the differences in sample preparation and nucleic acid
isolation would have a relevant influence on the consti-
tution of the specimens.
While some authors observed a correlation between
loss of mRNA expression and promoter methylation for
AKAP12 in other cancers [15], we did not find signifi-
cant evidence that this also takes place in the investi-
gated PDAC cell lines. Loss of protein expression also
failed to match promoter methylation as well as reduced
mRNA expression in the investigated cell lines. Interest-
ingly, we detected a correlation between increased SER-
PINB5 (MASPIN)m R N Ae x p r e s s i o na n di n c r e a s e d
propensity to metastasize. SERPINB5 is regarded as a
metastasis suppressor gene in breast cancer [16], but
has also been proposed as a detector of circulating
breast cancer cells [17]. It is involved in intestinal cancer
where its overexpression appears to coincide with tumor
progression and metastatic spread [18,19]. For pancrea-
tic cancer, conflicting roles of SERPINB5 have been
described: Hong et al. showed SERPINB5-transfected
PDAC cells to have reduced invasive ability [20] and
Kashima et al. found SERPINB5 expression to increase
with tumor progression from intraductal papillary muci-
nous neoplasm to non-invasive carcinomas but to
decrease in invasive carcinomas [21]. In contrast to
these reports of protective effects, overexpression of
SERPINB5 in PDAC was found to be associated with
worse postoperative survival and was an independent
adverse prognosticator for postoperative survival
[22-24]. Previous studies have suggested that SERPINB5
must be located at the cytoplasmic membrane in order
to perform its protective role, but the details of its func-
tion still remain unclear [16]. SERPINB5 is not
expressed in healthy pancreas and its expression is con-
trolled by promoter methylation [25,26]. Accordingly, in
this study, SERPINB5-methylated cell lines had more
than 100-fold reduced mRNA expression vs. unmethy-
lated cell lines and SERPINB5 methylation corresponded
to loss of protein expression. Additionally, a significant
correlation between SERPINB5 methylation levels and
PDAC cell line metastatic potential was detected. Thus,
an assay determining SERPINB5 promoter methylation,
or rather lack of methylation, may be considered as a
marker for pancreatic cancer. Functional analyses of the
role of SERPINB5 in PDAC and validation of its overex-
pression using resected specimens are necessary before
any conclusions regarding its usefulness as a diagnostic
or therapeutic option can be reached; this is the subject
of ongoing studies. However, the results of the present
study may be used to identify candidate genes for subse-
quent studies.
Conclusions
Our data suggests that of 11 investigated metastasis sup-
pressors only AKAP12 may be associated with a less
aggressive phenotype of PDAC, while SERPINB5
Figure 6 Protein expression of AKAP12 and SERPINB5. Western Blot, methylation status and mRNA expression of selected cell lines. SERPINB5
protein is lost in methylated cell lines along with mRNA expression while AKAP12 protein remains present in methylated cell lines.
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contrast to other tumor entities, metastasis suppressor
gene deregulation appears to be limited to a small num-
ber of known genes. These results underline the indivi-
dual tumor biology of PDAC and further emphasize the
need for specific markers and novel therapeutic targets
for this entity.
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